tafasitamab   Click here for help

GtoPdb Ligand ID: 11131

Synonyms: Minjuvi® | Monjuvi® | MOR-208 | MOR00208 | MOR208 | tafasitamab-cxix | Xmab5574
Approved drug Immunopharmacology Ligand
tafasitamab is an approved drug (FDA (2020), EMA (2021))
Compound class: Antibody
Comment: Tafasitamab (MOR208, formerly Xmab®5574) is a humanized Fc-engineered monoclonal antibody directed against CD19 that was developed by MorphoSys [4]. XmAb® antibodies are designed with modifications in their Fc domain (S239D/I332E mutations) that increase binding to Fcγ receptors on immune cells. This optimises the antibody's Fc-mediated effector function (i.e. antibody-dependent cell-mediated cytotoxicity, ADCC) [1,5]. At the beginning ot 2020, MorphoSys and Incyte Corporation entered into a collaboration and license agreement for the global development and commercialization of tafasitamab (MOR208).
Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2020)  |  EMA (2021)
International Nonproprietary Names Click here for help
INN number INN
10835 tafasitamab
Synonyms Click here for help
Minjuvi® | Monjuvi® | MOR-208 | MOR00208 | MOR208 | tafasitamab-cxix | Xmab5574
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 522
Other databases
GtoPdb PubChem SID 434122191
Search PubMed clinical trials tafasitamab
Search PubMed titles tafasitamab
Search PubMed titles/abstracts tafasitamab